Health Costs

Affordability and Spending

Beyond the Data: Are the Tradeoffs from Prior Authorization Worth It? 

In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs. He writes “Nothing makes American health care consumers more frustrated using the health system than prior authorization review. I know because they told us that, ranking prior authorization review far ahead of any other problems they have getting care and navigating the health care system, including getting appointments and understanding their bills.”

Affordable care act

ACA Marketplace Survey Feature Image - Website

Cost Concerns and Coverage Changes: A Follow-Up Survey of ACA Marketplace Enrollees

This KFF survey is a follow-up survey of adults who had ACA Marketplace insurance in 2025. The survey examines the cost concerns and coverage changes that these 2025 Marketplace enrollees are experiencing following the expiration of the enhanced premium tax credits. The survey finds that half of returning enrollees say their health care costs are “a lot higher” and most expect to cut back on basic household expenses to afford coverage.

Health System Tracker

How Does Health Spending in the U.S. Compare to Other Countries? While the U.S. still spends the most in total dollars, eight OECD nations had a higher percentage increase in per-person health spending in 2024.

 

How Does Cost Affect Access to Health Care? In 2024, about 1 in 6 adults reported delaying or not getting healthcare due to cost, including medical or mental health care.

 

How Do Health Expenditures Vary Across the Population? Five percent of the population made up nearly half of all health spendings, pending an average of $72,918 annually in 2023.

NHE explorer

National Health Spending Explorer: Get up-to-date information on U.S. health spending by federal and local governments, private companies, and individuals.

Filter

1,061 - 1,070 of 1,565 Results

  • The Good and Bad of Those Ubiquitous Drug Ads

    News Release

    In his latest column for The Wall Street Journal’s Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new Kaiser Family Foundation survey. All previous columns by Drew Altman are available online.

  • What New Data Tell Us About Doctor Choice

    News Release

    Is choice of doctors eroding? Drew Altman explores the rhetoric versus reality and why the issue resonates with Americans, in his latest column for The Wall Street Journal's Think Tank. All previous columns by Drew Altman are online.

  • Health of the Healthcare System

    Video

    Health of the Healthcare System is a diagnostic look at the state of our healthcare system. How does the U.S. healthcare system compare to health systems of other high-income countries, and how has it fared over time? Kaiser Health News and former-NPR reporter, Julie Rovner, takes us through a check-up of our system by assessing four key areas: how healthy we are, the quality of care we receive, how much it costs, and how accessible it is.

  • Health of the Healthcare System: An Overview

    Feature

    This slideshow accompanies the video, “Health of the Healthcare System,” a diagnostic look at the state of the U.S. healthcare system. It compares the United States to other countries in four key areas: health, quality of health care, cost of care, and accessibility.

  • How Have Diabetes Costs and Outcomes Changed Over Time in the U.S.?

    Feature

    In 2017, 7.2% of the U.S. population was diagnosed with diabetes - an 188% increase from 1980. This slideshow documents trends in health outcomes, quality of care, and spending on treatment for people in the U.S. with diabetes. It also looks at the costs of medications for treating diabetes, and U.S. health spending related to endocrine diseases.

  • The Good and Bad of Those Ubiquitous Drug Ads

    From Drew Altman

    In this column for The Wall Street Journal's Think Tank, Drew Altman examines the public’s mixed views about prescription drug ads and their impact on prescribing patterns, based on a new survey.